TTP, thrombotic thrombocytopenic purpura; VWF, von Willebrand factor; M, male; F, female; ND, not detected; NP, not performed; LT: low titre.
Complement activation in thrombotic microangiopathies
Article first published online: 1 NOV 2012
© 2012 Blackwell Publishing Ltd
British Journal of Haematology
Volume 160, Issue 3, pages 404–406, February 2013
How to Cite
Feng, S., Kroll, M. H., Nolasco, L., Moake, J. and Afshar-Kharghan, V. (2013), Complement activation in thrombotic microangiopathies. British Journal of Haematology, 160: 404–406. doi: 10.1111/bjh.12112
- Issue published online: 17 JAN 2013
- Article first published online: 1 NOV 2012
- thrombotic haemolytic anaemias;
- von Willebrand factor
The thrombotic microangiopathies (TMA) are a group of disorders defined by the presence of microangiopathic haemolytic anaemia and thrombocytopenia. The most common of these is thrombotic thrombocytopenic purpura (TTP), which is a systemic disorder of microvascular thromboses due to deficiency of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13). A less common TMA is the atypical haemolytic uraemic syndrome (aHUS), which is a renal vascular TMA caused by complement dysregulation.
Despite overlapping clinical and pathological manifestations, TTP and aHUS have distinct aetiologies. TTP is often caused by a deficiency of ADAMTS13 as a result of gene mutations or acquired autoantibodies (Tsai, 2006). Atypical HUS is caused by defects of regulation and/or excessive activation of the alternative complement pathway (Kavanagh & Goodship, 2010).
The mechanism by which complement dysregulation contributes to aHUS is not precisely defined, although complement-mediated glomerular endothelial injury and enhanced complement-mediated platelet activation are probably involved (Stahl et al, 2008). Similarly, triggers and co-factors directing systemic platelet deposition in TTP are not completely understood. Evidence that complement activation might play a role in TTP (Noris et al, 1999; Ruiz-Torres et al, 2005; Reti et al, 2012) raises the possibility of a cross-talk between ADAMTS13/ultra-large von Willebrand factor (ULVWF) and the complement system.
We studied plasma samples of 81 patients diagnosed with TMA according to clinical criteria for functional abnormalities in both ADAMTS13 and complement regulation. Citrated platelet-poor plasma samples were obtained for testing before the initial plasma infusion or exchange procedures. All patients had microangiopathic haemolytic anaemia and thrombocytopenia without an alternative cause, and had been treated with either plasma infusion or plasma exchanges. None of our patients had acute renal failure. Samples for analysis of DNA were not obtained/stored from this group of patients. All human subject studies were conducted according to the approved institutional review board protocols in the Rice University and University of Texas M.D. Anderson Cancer Center.
ADAMTS13 activity was measured by: (i) the rate of cleavage of a substrate that contains 73 amino acids of the A2 domain of von Willebrand factor (VWF) with fluorescence resonance energy transfer (FRET) tags on either side of the cleavage site for ADAMTS13 (FRETS-VWF73), according to the manufacturer's protocol (Hologic Gen-Probe, San Diego, CA, USA); and (ii) cleavage of urea-treated ULVWF multimers (obtained from human umbilical vein endothelial cell supernatant) by citrated patient plasma, followed by VWF multimeric analysis using sodium dodecyl sulphate-1% agarose electrophoresis and Western-blotting with anti-VWF antibody. This is a modification of the method described by Furlan et al (1998). The presence or absence of ADAMTS13 inhibitors was determined by measuring cleavage of urea-treated ULVWF multimers before and after mixing normal citrated plasma with an equal volume of patient citrated plasma (Furlan et al, 1998).
Complement activity was measured by the haemolysis of sheep erythrocytes after incubation with human serum or plasma according to modified techniques from Sanchez-Corral et al (2004).
Factor H-depleted plasma causes complement-induced lysis of sheep erythrocytes with the visually apparent release of haemoglobin. Pooled normal plasma or serum caused 7% and 8% haemolysis of sheep erythrocytes, respectively. Optimal dilution of plasma or serum for the assay was determined to be between 4/100 and 6/100, and optimal incubation time was 10 min.
Sixty percent (49/81) of TMA patients had severe ADAMTS13 deficiency (less than 10% activity). Eighty percent (65/81) of our patients' plasma samples caused little to no haemolysis of sheep erythrocytes (median of 10%; range of 0–15%). In contrast, 20% (16/81) of the patients' samples showed significant haemolysis (median of 60% haemolysis; range of 23–89%) (Fig 1). Sixteen percent (8/49) of plasma samples from TTP patients with severe ADAMTS13 deficiency caused increased haemolysis. Only one of the eight patients with concurrent excessive complement-induced haemolysis and severe ADAMTS13 deficiency had detectable antibody (in low titre) against ADAMTS13 (Table 1). Twenty-five percent (8/32) of plasma samples from patients who did not have severe ADAMTS13 deficiency also caused increased haemolysis.
|ADAMTS13 function (%)|
Severe deficiency of functional ADAMTS13 is associated with TTP; however, many patients with a TTP-like syndrome have normal ADAMTS13 levels, as did 40% (32/81) of the patients in our study. There are several reports of patients with reduced ADAMTS13 function who either did not develop TTP, or did so later in life (Noris et al, 2005). These observations raise the possibility of the presence of additional factors besides ADAMTS13 deficiency involved in the pathophysiology of TTP (Ruiz-Torres et al, 2005; Reti et al, 2012; Noris et al, 2005; Chapin et al, 2012). Activation of the complement system in both familial (Noris et al, 1999) and acquired TTP (Reti et al, 2012) has been reported, based on the lower concentration of C3 and elevated levels of complement activation products (C3a and sC5b-9) in the sera of patients with acute TTP, and deposition of C3 and C5b-9 on endothelial cell exposed to TTP sera (Ruiz-Torres et al, 2005). We studied activity of the alternative complement pathway in 81 patients with the clinical diagnosis of TTP-like TMA requiring plasma infusion and/or plasma exchange. Some patients with severe ADAMTS13 deficiency (8/49; 16%) or TTP-like TMA (8/32; 25%), had elevated plasma complement activity. We did not detect an increased titre of ADAMTS13 inhibitor in ADAMTS13-deficient TTP patients with complement dysregulation, and the majority of these patients (5/8; 68%) had a history of familial or recurrent TTP (Table 1).
Our data suggest that the complement system may be an important co-factor involved in the pathogenesis of TMA. Excessive alternative pathway activity occurred in a significant number of TTP patients, indicating that concurrent defects in ADAMTS13 and complement regulation may occur more frequently than previously reported (Noris et al, 2005; Chapin et al, 2012). In addition, our findings indicate that excessive alternative pathway activity can be associated with a TTP-like TMA in some patients who do not have severe deficiencies of ADAMTS13. Further genetic studies of patients with the clinical diagnosis of TTP may be informative.
S.F. performed the research; M.H.K. designed the research study and interpreted the data; L.N. performed the research, J.M. designed the research study and interpreted the data, and V.A.-K. designed the research study, interpreted the data, and wrote the paper.
- 2012) Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. British Journal of Haematology, 157, 772–774. , , & (
- 1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome [see comments]. The New England Journal of Medicine, 339, 1578–1584. , , , , , , , , , , & (
- 2010) Atypical hemolytic uremic syndrome. Current Opinion in Hematology, 17, 432–438. & (
- 1999) Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Journal of American Society of Nephrology, 10, 281–293. , , , , , , , & (
- 2005) Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. Journal of American Society of Nephrology, 16, 1177–1183. , , , , , , , , & (
- 2012) Complement activation in thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 10, 791–798. , , , , , , , , , , & (
- 2005) Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 93, 443–452. , , , , , , , , , & (
- 2004) Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Molecular Immunology, 41, 81–84. , , & (
- 2008) Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood, 111, 5307–5315. , , , , , , , , & (
- 2006) The molecular biology of thrombotic microangiopathy. Kidney International, 70, 16–23. (